<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981808</url>
  </required_header>
  <id_info>
    <org_study_id>N-20200068</org_study_id>
    <nct_id>NCT04981808</nct_id>
  </id_info>
  <brief_title>Diabetes teleMonitoring of Patients in Insulin Therapy</brief_title>
  <acronym>DiaMonT</acronym>
  <official_title>The Diabetes teleMonitoring of Patients in Insulin Therapy (DiaMonT) Trial: Study Protocol for a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steno Diabetes Center Sjaelland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glooko</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is an open-label randomized controlled trial. Patients with T2D on insulin therapy&#xD;
      will be randomized to a telemonitoring group (intervention) and a usual care group (control).&#xD;
      The telemonitoring group will use various devices at home. Hospital staff will monitor their&#xD;
      data for a period of three months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DiaMonT trial is an open-label randomized controlled trial with a trial period of three&#xD;
      months conducted. The trial will be conducted in two sites in Denmark: Steno Diabetes Center&#xD;
      North Jutland and Steno Diabetes Center Zealand. Patients with T2D on insulin therapy will be&#xD;
      randomized (1:1) to a telemonitoring group (intervention) or a usual care group (control).&#xD;
      The telemonitoring group will use an insulin pen, an activity tracker, a CGM, and a&#xD;
      smartphone application throughout the trial period. Hospital staff (lab technicians and&#xD;
      nurses) will monitor the telemonitoring groups' data and contact the subjects by telephone&#xD;
      repeatedly throughout the trial period. The usual care group will use a blinded CGM the first&#xD;
      and last 20 days of the trial and will use a blinded insulin pen for the entire period. The&#xD;
      usual care groups' data will not be monitored during the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CGM time in range</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Change in CGM time in range (3,9-10,0 mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of HbA1c</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily units of insulin</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Change in total daily dose of insulin (units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below CGM range</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Change in time below range (CGM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above CGM range</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Change in time above range (CGM)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of CGM days worn</measure>
    <time_frame>During the intervention</time_frame>
    <description>Number of days that the subjects wear the CGM</description>
  </other_outcome>
  <other_outcome>
    <measure>CGM percentage of time active</measure>
    <time_frame>During the intervention</time_frame>
    <description>Percentage of time that the CGM is active</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean glucose</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Mean glucose levels (mmol/l) measured by CGM</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Glycemic variability - percentage of cofficient of variation</description>
  </other_outcome>
  <other_outcome>
    <measure>Time in hyperglycemia</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Time in hyperglycemia (&gt;13,9 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time in hypoglycemia</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Time in hypoglycemia (&lt;3,0 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Episodes of hyperglycemia</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Number of episodes of hyperglycemia (&gt;13,9 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Episodes of hypoglycemia</measure>
    <time_frame>At baseline to three months after randomization</time_frame>
    <description>Number of episodes in hypoglycemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Use of the telemonitoring equipment</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>The frequency of use of the telemonitoring equipment</description>
  </other_outcome>
  <other_outcome>
    <measure>Telemonitoring usability</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Telemonitoring satisfaction and usability measured by the Telemonitoring Usability Questionnaire (TUQ). Minimum value =1, maximum value =7. A higher score = a better outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Diabetes-related quality of life</measure>
    <time_frame>From baseline to three months after randomization</time_frame>
    <description>Diabetes-related quality of life measured by the DIDP Questionnaire. Ranges from &quot;very negative&quot; to &quot;very positive&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>From baseline to three months after randomization</time_frame>
    <description>Health-related quality of life measured by the Short Form 12 (SF-12). Options are not numeric</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes Treated With Insulin</condition>
  <arm_group>
    <arm_group_label>Telemonitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be telemonitored. All subject will use a CGM, a fit bit, and a smart pen during the entire trial period. Staff at the endocinology clinics will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The subjects will wear a blinded CGM the first and final 20 days of the trial. The subjects will use a blinded smart pen throughout the trial period. Hence, the subjects are unable to see their measured data during the trial, and they will not be monitored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Telemonitoring</intervention_name>
    <description>Telemonitoring of CGM and insulin pen data</description>
    <arm_group_label>Telemonitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  T2D diagnosis for ≥ 12 months&#xD;
&#xD;
          -  Residence in Region North Denmark or Region Zealand&#xD;
&#xD;
          -  In treatment with insulin&#xD;
&#xD;
          -  Being able to use a smartphone along with the other devices to be used in the trial&#xD;
&#xD;
          -  Able to understand and read Danish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding,&#xD;
&#xD;
          -  Major surgery planned during the trial period&#xD;
&#xD;
          -  Participation in other trials&#xD;
&#xD;
          -  Terms that, in the opinion of the investigator or subinvestigators, render the&#xD;
             participant unfit to conduct the trial, including lack of understanding of the trial&#xD;
             or lack of physical or cognitive ability to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Vestergaard</investigator_full_name>
    <investigator_title>MD, professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Telemedicine</keyword>
  <keyword>Telehealth</keyword>
  <keyword>Telemonitoring</keyword>
  <keyword>CGM</keyword>
  <keyword>Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

